GlassScriptPhysician profile
David L Mellman
NPI 1972688554
$11,948.56
in general payments reported to CMS, 2019-2025
52 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $1,509 · 2021: $2,644 · 2022: $1,816 · 2023: $1,667 · 2024: $1,738 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,455 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,455.13 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,156.52 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $1,087.27 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $978.46 | 2019-2025 | |
| Novo Nordisk INC | $843.90 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $797.53 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Lilly USA, LLC | $742.83 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Astellas Pharma US INC | $501.69 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $444.95 | 2019-2025 | |
| Allergan, INC. | $442.19 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $381.11 | 2019-2025 | Spravato, Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $368.99 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $334.73 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $323.42 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.63 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $294.46 | 2022-2024 | Quviviq |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.